← Back to Screener
Verrica Pharmaceuticals Inc. Common Stock (VRCA)
Price$6.32
Favorite Metrics
Price vs S&P 500 (26W)43.91%
Price vs S&P 500 (4W)6.47%
Market Capitalization$108.57M
All Metrics
Book Value / Share (Quarterly)$1.44
P/TBV (Annual)3.97x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)57.94%
Cash Flow / Share (Quarterly)$-1.03
Price vs S&P 500 (YTD)-28.09%
Gross Margin (TTM)90.33%
Net Profit Margin (TTM)-50.27%
EPS (TTM)$-1.61
10-Day Avg Trading Volume0.10M
EPS Excl Extra (TTM)$-1.61
EPS (Annual)$-1.68
ROI (Annual)-69.35%
Gross Margin (Annual)90.33%
Net Profit Margin (5Y Avg)-586.69%
Cash / Share (Quarterly)$1.75
Revenue Growth QoQ (YoY)1380.23%
ROA (Last FY)-37.95%
Revenue Growth TTM (YoY)370.22%
EBITD / Share (TTM)$-1.24
ROE (5Y Avg)-141.89%
Operating Margin (TTM)-38.56%
Cash Flow / Share (Annual)$-1.03
P/B Ratio4.39x
P/B Ratio (Quarterly)3.19x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.23x
Net Interest Coverage (TTM)-3.29x
ROA (TTM)-42.26%
EPS Incl Extra (Annual)$-1.68
Current Ratio (Annual)2.59x
Quick Ratio (Quarterly)2.28x
3-Month Avg Trading Volume0.15M
52-Week Price Return31.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.01
P/S Ratio (Annual)3.05x
Asset Turnover (Annual)0.75x
52-Week High$9.82
Operating Margin (5Y Avg)-540.49%
EPS Excl Extra (Annual)$-1.68
CapEx CAGR (5Y)-47.55%
Tangible BV CAGR (5Y)36.44%
26-Week Price Return52.66%
Quick Ratio (Annual)2.28x
13-Week Price Return-20.50%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)2.59x
Enterprise Value$79.471
Asset Turnover (TTM)0.84x
Book Value / Share Growth (5Y)-10.58%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-50.27%
Cash / Share (Annual)$1.75
3-Month Return Std Dev84.14%
Net Income / Employee (TTM)$-0
ROE (Last FY)-72.29%
Net Interest Coverage (Annual)-1.71x
EPS Basic Excl Extra (Annual)$-1.68
Receivables Turnover (TTM)13.40x
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-1.61
ROI (TTM)-31.31%
P/S Ratio (TTM)3.05x
Pretax Margin (5Y Avg)-586.69%
Revenue / Share (Annual)$3.34
Tangible BV / Share (Annual)$0.97
Price vs S&P 500 (52W)-3.15%
Year-to-Date Return-23.95%
5-Day Price Return12.46%
EPS Normalized (Annual)$-1.68
ROA (5Y Avg)-72.01%
Net Profit Margin (Annual)-50.27%
Month-to-Date Return19.47%
Cash Flow / Share (TTM)$-1.08
EBITD / Share (Annual)$-1.24
Operating Margin (Annual)-38.56%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-68.97%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.61
P/TBV (Quarterly)3.76x
P/B Ratio (Annual)3.19x
Inventory Turnover (TTM)1.46x
Pretax Margin (TTM)-50.27%
Book Value / Share (Annual)$1.44
Price vs S&P 500 (13W)-23.37%
Beta1.57x
Revenue / Share (TTM)$2.52
ROE (TTM)-32.63%
52-Week Low$3.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VRCAVerrica Pharmaceuticals Inc. Common Stock | 3.05x | 370.22% | 90.33% | — | $6.32 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Verrica Pharmaceuticals is a dermatology therapeutics company developing novel treatments for contagious viral skin diseases. Its lead product candidate, VP-102, targets molluscum contagiosum and common warts, addressing significant market opportunities in pediatric and adult populations.